Description
Created On: 2020-07-15
Record Count: 8
Primary Industries
- Drugs
- Disease
- Therapeutic
- Diagnostic
- Cancer
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 203285
Licensor grants a non-transferable, non-exclusive license, with the right to sublicense, under the Licensor Other Patent Rights solely to the extent reasonably necessary to make, use (including in activities directed at the research and Development of Licensed Compounds), have made, sell, offer to sell, export and import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.
6,670,386 – Bicyclic modulators of androgen receptor function
The licensed compounds and patents relate to controlling various diseases and cancers.
IPSCIO Record ID: 203480
The Parties are establishing a collaborative effort to perform research and develop and market products for the prevention, diagnosis, and treatment of skeletal muscle disorders.
For the Termination of the Multi-Project Collaboration Agreement and Overview and Management of Collaboration portion of this Collaboration agreement, the Multi-Project Collaboration Agreement is hereby terminated, and contrary to the Multi-Project Collaboration Agreement, Licensee shall own all Inventions discovered by employees of Licensee as part of any Licensee Retained Project and having no utility in the Field as of the Effective Date.
Licensor grants an exclusive License under its Patents and Know-how whether solely owned by Licensor or jointly owned with Licensee which were conceived and reduced to practice in connection with any Licensee Retained Project at any time through December 31, 2000 and as of December 31, 2000 have no known use in the Field or in any Licensor Retained Project to make, have made, use, import, offer for sale and sell any products for the prevention, diagnosis, or treatment of any diseases or disorders in humans or animals in connection with any Licensee Retained Project.
Licensor grants a non-exclusive License under its Patents and Know-how which were conceived and reduced to practice in connection with any Licensee Retained Project at any time through December 31, 2000 and as of December 31, 2000 have known use in the Field or in any Licensor Retained Project, to make, have made, use, import, offer for sale and sell any products for the prevention, diagnosis, or treatment of any disease or disorder in humans or animals in connection with any Licensee Retained Project.
Licensor grants a non-exclusive License under its Patents and Know-how conceived and reduced to practice in connection with any Mutual Retained Project at any time through December 31, 2000, to make, have made, use, import, offer for sale and sell any products for the prevention, diagnosis, or treatment of any disease or disorder in humans or animals.
For the Scope of Collaboration, the Parties will work together to research, develop and commercialize Lead Compounds pursuant to this Agreement in the Territory.
Agrin means the compounds claimed in the United States Patent Application Serial Number 08/644,271 and any continuations, divisionals or continuation-in-parts thereof, and any molecules representing one or more amino acid substitutions, deletions, or additions derived therefrom.
Compound means a chemical entity, which is not Excluded Technology, with research or commercial utility in the Field for methods of research, diagnosis, treatment or prevention of any disease or disorder in humans or animals, and which is conceived and/or reduced to practice by Licensee, or acquired by Licensee from a Third Party with the right to sublicense, before or during the Research Term; or is conceived and/or reduced to practice by Licensor, or acquired by Licensor from a Third Party with the right to sublicense, prior to or during the Research Term.
GPCR means a G-protein coupled receptor.
Field means the collective areas in which the Parties shall collaborate encompassing the discovery, development, supply and commercialization of products or processes in the Muscle Field, the GPCR Field or the DDR Field.
DDR Field means the discovery, development, supply and commercialization of products or processes that modulate the function of the receptor tyrosine kinases DDR1 and/or DDR2 (or any receptor having at least seventy-five percent (75%) homology with DDR1 or DDR2) whose biological action is primarily due to this modulation.
GPCR Field means the discovery, development, supply and commercialization of products or processes that directly bind and/or modulate the function of the twelve GPCRs.
Muscle Field means the discovery, development, supply and/or commercialization of products (except MuSK and/or Agrin) or processes that diagnose, prevent and/or treat conditions in humans and animals associated with the promotion or protection of skeletal muscle mass or function (including, without limitation, the diagnosis, treatment or prevention of muscle atrophy or sarcopenia).
IPSCIO Record ID: 204359
Sphingosine-1-phosphate receptor 1 (S1P receptor 1 or S1P1), also known as endothelial differentiation gene 1 (EDG1) is a protein that in humans is encoded by the S1PR1 gene.
S1P1 is designed for treatment of autoimmune and inflammatory disorders.
IPSCIO Record ID: 237208
The Parties are establishing a collaborative effort to perform research and develop and market products for the prevention, diagnosis, and treatment of skeletal muscle disorders.
Either Party may become an Opting Out Party with respect to a Lead Compound, Development Compound or Marketed Compound, either in total or on a country-by-country basis. The Proceeding Party may proceed to research, develop and/or market such Compound at its own expense. The Opting Out Party shall grant licenses to the Proceeding Party.
For the License Grants during Research Term, Inventions Having Utility, Licensor grants Licensee a Sole License under Licensor Patent Rights and Licensor Know-how to make, have made, use, import, offer for sale and sell Licensor Technology in the Field.
Licensor also grants Licensee, for research purposes only in the Field, a Sole License under Licensor Patent Rights and Licensor Know-how to make, have made, and use small molecule Research Compounds that have not met Success Criteria.
Sole License shall mean a non-exclusive license in the Territory under Know-how or a Patent, without the right to sublicense, granted by a Licensor Party to the other Licensee Party in the Field, wherein the Licensor Party shall not grant any Third Party rights in the Field under the Know-how or Patent to the subject matter of the license.
With respect to Inventions made as a direct result of work done under this Agreement during the Research Term and owned solely or jointly by a Party wherein the Invention has utility in the Field, each Party grants to the other the right of first negotiation to obtain from the other Party exclusive rights outside the Field in the Territory under reasonable terms for any such Invention.
For the Rights upon Termination of the Research Term, Inventions Having Utility in the Field, upon expiration of the Research Term, the Sole Licenses and rights of first negotiation granted by the Parties shall terminate, and, With respect to Licensor Inventions having a utility in the Field, Licensor shall grant Licensee a non-exclusive license under Licensor Know-how and Licensor Patent Rights, without the right to sublicense, to make, have made, and use Licensor Technology for the purpose of discovering, developing and/or commercializing Compounds (other than small molecules, DNA sequences, proteins and peptides that are covered by Licensor Inventions identified during the Research Term or Tail Period (Licensor Compounds) in the Field.
In addition, Licensor shall grant to Licensee a non-exclusive license under Licensor Know-how and Licensor Patent Rights, without the right to sublicense, to make, have made, and use Licensor Compounds solely for research purposes. For clarity, this nonexclusive license to Licensor Technology and Licensor Compounds does not include the right to have sold or sell Licensor Technology and Licensor Compounds, under Licensor Know-how and Licensor Patent Rights.
For License Grants to Inventions Having No Utility in The Field, each Party shall have the right of first negotiation to obtain exclusive rights outside the Field and in the Territory under reasonable terms consistent with those set forth herein for any such Invention owned jointly with the other Party.
– Licensor shall have the right of first negotiation to obtain exclusive rights outside the Field and in the Territory under reasonable terms consistent with those set forth herein for any such Invention having cardiovascular utility owned solely by Licensee or its Affiliates.
– Licensee shall have the right of first negotiation to obtain exclusive rights outside the Field and in the Territory under reasonable terms consistent with those set forth herein for any such Invention having cancer utility and/or immunosuppressive utility (which term does not include utility in arthritis) owned solely by Licensor or its Affiliates.
For the Grant of License by Opting Out Party, In the event a Party becomes an Opting Out Party with respect to a Development Compound in its entirety or on a country-by-country basis, then the license granted by the Opting Out Party to the Proceeding Party shall be an exclusive license including as to the Opting Out Party, with the right to sublicense, to make, have made, use, import and sell such Development Compound under the Patents, Know-how, trademarks and copyrights regarding that Compound owned in whole or in part by the Opting Out Party. The license shall be in all countries of the Territory in which Opting Out has been deemed to occur.
A Party shall not grant any license to a Third Party.
GPCR means a G-protein coupled receptor.
Field means the collective areas in which the Parties shall collaborate encompassing the discovery, development, supply and commercialization of products or processes in the Muscle Field, the GPCR Field or the DDR Field.
DDR Field means the discovery, development, supply and commercialization of products or processes that modulate the function of the receptor tyrosine kinases DDR1 and/or DDR2 (or any receptor having at least seventy-five percent (75%) homology with DDR1 or DDR2) whose biological action is primarily due to this modulation.
GPCR Field means the discovery, development, supply and commercialization of products or processes that directly bind and/or modulate the function of the twelve GPCRs.
Muscle Field means the discovery, development, supply and/or commercialization of products (except MuSK and/or Agrin) or processes that diagnose, prevent and/or treat conditions in humans and animals associated with the promotion or protection of skeletal muscle mass or function (including, without limitation, the diagnosis, treatment or prevention of muscle atrophy or sarcopenia).
IPSCIO Record ID: 233486
For the Evaluation License Grant, Licensor grants, during the Option Period, a non-exclusive, limited research-use only license, without the right to sublicense, except to subcontractors as provided in this Agreement, under the Licensor Technology solely to perform Preliminary Evaluation Work and Evaluation Studies as provided in this Agreement.
For the Muscarinic Product Development and Commercialization License, Licensor grants, during the Term, an exclusive, worldwide license, with the right to sublicense even through multiple tiers of sublicense, under Licensor Technology and Licensor’s interest in Joint Patents, to develop, make, have made, use, distribute, promote, sell, offer for sale, have sold, import, and export Muscarinic Products in the Muscarinic Field.
For the Fixed Co-Formulation Product Development and Commercialization Exclusive License, effective only upon exercise of the Option and payment in full of the Option Exercise Fee, Licensor grants, during the Term, an exclusive, worldwide license, with the right to sublicense even through multiple tiers of sublicense, under Licensor Technology to develop, make, have made, use, distribute, promote, sell, offer for sale, have sold, import, and export Fixed Co-Formulation Products in the Sleep Field. For the avoidance of doubt, the license granted excludes any license under Licensor Technology to develop, make, have made, use, distribute, promote, sell, offer for sale, have sold, import, and export N-Dealkylated Licensed Compound Metabolites, and any license under Licensor Technology containing claims directed only to N-Dealkylated Licensed Compound Metabolites.
For the Fixed Co-Formulation Product Development and Commercialization Non-Exclusive License, Licensor grants, during the Term, a non-exclusive, worldwide license, with the right to sublicense even through multiple tiers of sublicense, under Licensor Technology and any other Patents directed to N-Dealkylated Licensed Compound Metabolites that are Controlled by Licensor to develop, make, have made, use, distribute, promote, sell, offer for sale, have sold, import, and export Fixed Co-Formulation Products in the Sleep Field.
For the Grant of Option, Licensor grants an option, exercisable during the Final Evaluation Period with respect to one (1) Chosen Compound, to obtain an exclusive, worldwide license, with the right to sublicense, under the Licensor Technology to develop, make, have made, use, distribute, distribute for sale, promote, sell, offer for sale, have sold, or import Fixed Co-Formulation Products in the Sleep Field.
The Licensor Know-How, beyond the patents, during the research term, excludes any such information relating to Licensors compounds known as -103 and -104, -104 Analogs and/or Topical Eyecare Compounds, which is Confidential Information of Licensor.
Licensor Muscarinic Compounds shall mean any compound Controlled by Licensor on the Effective Date, the primary mode of action of which is [activity as a selective] allosteric modulator, agonist, or antagonist of any one (1) or more of the five (5) muscarinic receptor subtypes, including, without limitation, Licensors proprietary [m3 antagonists), but subject to exclusion of [m1] Agonists. Notwithstanding the foregoing or any other provision of this Agreement to the contrary, neither Licensors compound known as -104 (N-desmethylclozapine) nor any -104 Analogs shall be considered Licensor Muscarinic Compounds for purposes of this Agreement.
Muscarinic receptors are receptors that respond to acetylcholine, a neurotransmitter in the central nervous system.
Sleep Field shall mean the treatment, prevention, or management, or any combination thereof, as a primary objective, of any condition, disturbance, disease, or disorder in humans the principal effect(s) of which are on sleep time, sleep quality, sleep onset, sleep architecture, or sleep maintenance, or to disrupt or disturb normal sleep or sleep patterns, including without limitation: insomnia, including without limitation transient, chronic, primary, and secondary insomnia; jet lag; bruxism; breathing related sleep disorders, including without limitation sleep apnea; sleep terror disorders, including sleep terrors and pavor nocturnus; sleep walking disorders; sleep paralysis; circadian rhythm sleep disorders, including without limitation delayed sleep phase syndrome, and advanced phase sleep syndrome; shift work sleep disorder; sleep enuresis; sudden infant death syndrome; narcolepsy; periodic limb movement disorder; rapid eye movement behavior disorder; other parasomnias; and other dysomnias, and also including, without limitation, any such condition, disturbance, disease, or disorder where the treatment, prevention, or management, or any combination thereof, of any such condition, disturbance, disease, or disorder may result, as a secondary objective, in [improving cognitive function, alertness, physical dexterity, coordination, symptoms of fatigue, and other detrimental symptoms associated with or arising from any of the foregoing conditions, disturbances, diseases, or disorders.
IPSCIO Record ID: 237218
For the Licensee Commercialization License, Limited Partial Conversion to Non-exclusivity, subject to Licensors limited right to manufacture Collaboration Compounds and Covered Products, Licensor grants an exclusive, even as to Licensor, world-wide, royalty-bearing right and sublicense in the Field throughout the Territory, with the right to grant further sublicenses in accordance with the terms of this Agreement, under the ASU Licensed Technology to develop, make, have made, use, sell, offer for sale, have sold and export Covered Products.
Licensor grants an exclusive, even as to Licensor, world-wide right and license in the Field throughout the Territory, with the right to grant sublicenses in accordance with the terms of this Agreement, under the Licensor Licensed Technology, the Licensor Collaboration Technology and Licensors interest in the Joint Collaboration Technology to develop, make, have made, use, sell, offer for sale, have sold and export Covered Products.
For the Mutual Ex-Field Licenses, Licensor grants a perpetual, non-exclusive, world-wide right and license, with the right to grant sublicenses, under the Licensor Collaboration Technology and Joint Collaboration Technology for all purposes outside the Field.
Collaboration Compound shall mean any chemical compound, the composition of matter and/or method of use of which is, or is deemed to be, covered by the ASU Licensed Technology, the Licensor Licensed Technology and/or the OXiGENE Collaboration Technology, and that is the subject of any of the research, development, commercialization and/or marketing activities contemplated by this Agreement. While the Parties intend CA4P to be the initial Collaboration Compound, other compounds may be selected as Collaboration Compounds in addition to, or in lieu of, CA4P.
Combretastatin shall mean any cancer cell growth inhibitory substance derived from the bush willow Combretum caffrum.
CA4P shall mean the chemical compound having the chemical name Combretastatin A4 phosphate.
IPSCIO Record ID: 233459
– a sole and exclusive, including with regard to Licensor and its Affiliates, perpetual, worldwide license, with the right to grant sublicenses, under Licensors right, title, and interest in and to the Licensor Patents, the Licensor Know-How, the Joint Patents and the Joint Know-How to develop, modify, improve, make, have made, use, have used, import, export, offer for sale, sell, and have sold the Licensed Compound, the Licensed Product and any Improvements thereto within the Field; and
– a sole and exclusive, including with regard to Licensor and its Affiliates, perpetual, worldwide license, with the right to grant sublicenses, under Licensors right, title, and interest in and to the Licensor Patents, the Licensor Know-How, the Joint Patents and the Joint Know-How to use the Manufacturing Processes to Manufacture the Licensed Compound and the Licensed Product and any Improvements thereto.
Licensee has made an initial three million dollar $3,000,000 equity investment in Licensor in an related stock purchase agreement.
Licensed Compound shall mean all compounds referenced in the Licensor Patents listed, in both acid and salt forms thereof, including without limitation, R-Flurbiprofen, which is also known according to Licensors designation as E-7869, and any Improvements to all such compounds.
Licensed Product shall mean a product or products which contain(s) the Licensed Compound as an active ingredient.
Licensor developed the cancer drug , which will now be known as MPC-7869, for its potential to treat prostate and colon cancers. The drug compound represents a novel, highly specific approach to cancer therapy that, unlike widely used chemotherapy drugs, does not show generalized toxicity or its corresponding side-effect profiles. MPC-7869 appears to regulate the activity of NFkB, a transcriptional activator implicated in cancer and inflammatory diseases.
Drug compound, E-7869 is for the treatment of cancer.
IPSCIO Record ID: 203444
– to Develop, have Developed, make, have made, and use the Licensed Compound and Licensed Product in the Field, and
– to sell, offer for sale, register, Commercialize and otherwise exploit the Licensed Product in the Field; provided that notwithstanding the exclusive rights granted to Licensee in the foregoing grant, Licensor shall retain the limited right to use the Licensor Intellectual Property to the extent necessary to perform its express obligations under this Agreement, including the Clinical Development Plan, to conduct the Licensor Clinical Studies, subject to the approval of the Joint Steering Committee, and as otherwise agreed to in writing by the Parties.
The exclusivity of the sublicense granted under such Licensor Intellectual Property is subject to the applicable non-exclusivity terms in the another Agreement.
Included with this agreement is also a non-exclusive, non-sublicensable, except to subcontractors as
permitted under this Agreement, solely to permit such subcontractors to perform Licensors assigned responsibilities under the Clinical Development Plan, royalty-free, fully-paid right and license, by Licensee to Licensor under the Licensee Know-How and Licensee Patent Rights, solely to the extent necessary to conduct the activities assigned to Licensor by the Joint Steering Committee under the Clinical Development Plan.
TRPM-2 Antisense Therapy;
TRPM-2 Antisense Therapy and Combination composition;
TRPM-2 Antisense Therapy Using ai Oligonucleotide Having 2-0-(2- Methoxy)Ethyl Modifications Compound;
Chemo-and radiation-sensitization or cancer by antisense TRPM-2 oligodcoxynucleotides;
Treatment of Melanoma by Reduction in Clusterin Levels;
Clusterin antisense therapy for treatment of cancer;
Treatment of Cancer By Perturbation of Clusterin Levels;
Human Type 2 RNASE H;
Gapped Oligonucleotides, Directed to: Gapmer and Hemimer Compounds with 2-O-ALKYL modifications;
2-O-Modified Nucleosides and Phosphoramidites; and others.
The collaboration agreement is for developing and commercializing OGX-011. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance. OGX-011 is expected to be used as adjunct therapy to enhance the effectiveness of chemotherapy and has shown promising results when added to currently available chemotherapies in several tumor types addressing a significant unmet medical need.
